Cargando…

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital....

Descripción completa

Detalles Bibliográficos
Autores principales:	Egaña, Larraitz, Auzmendi-Iriarte, Jaione, Andermatten, Joaquin, Villanua, Jorge, Ruiz, Irune, Elua-Pinin, Alejandro, Aldaz, Paula, Querejeta, Arrate, Sarasqueta, Cristina, Zubia, Felix, Matheu, Ander, Samprón, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595088/ https://www.ncbi.nlm.nih.gov/pubmed/33116181 http://dx.doi.org/10.1038/s41598-020-75477-9

Ejemplares similares

PR-LncRNA signature regulates glioma cell activity through expression of SOX factors
por: Torres-Bayona, Sergio, et al.
Publicado: (2018)

Author Correction: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors
por: Torres-Bayona, Sergio, et al.
Publicado: (2022)

Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
por: Saenz-Antoñanzas, Ander, et al.
Publicado: (2019)

Chaperone-Mediated Autophagy Controls Proteomic and Transcriptomic Pathways to Maintain Glioma Stem Cell Activity
por: Auzmendi-Iriarte, Jaione, et al.
Publicado: (2022)

CRISPR/Cas9 Deletion of SOX2 Regulatory Region 2 (SRR2) Decreases SOX2 Malignant Activity in Glioblastoma
por: Saenz-Antoñanzas, Ander, et al.
Publicado: (2021)

Impact of Chaperone-Mediated Autophagy in Brain Aging: Neurodegenerative Diseases and Glioblastoma
por: Auzmendi-Iriarte, Jaione, et al.
Publicado: (2021)

Targeting SOX2 as a Therapeutic Strategy in Glioblastoma
por: Garros-Regulez, Laura, et al.
Publicado: (2016)

mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance
por: Garros-Regulez, Laura, et al.
Publicado: (2016)

Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment
por: Iturrioz-Rodríguez, Nerea, et al.
Publicado: (2023)

Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma
por: Aldaz, Paula, et al.
Publicado: (2021)

Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma
por: Auzmendi-Iriarte, Jaione, et al.
Publicado: (2020)

SOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycin
por: Carrasco-Garcia, Estefania, et al.
Publicado: (2016)

High SOX9 Maintains Glioma Stem Cell Activity through a Regulatory Loop Involving STAT3 and PML
por: Aldaz, Paula, et al.
Publicado: (2022)

Oncogenic activity of SOX1 in glioblastoma
por: Garcia, Idoia, et al.
Publicado: (2017)

SIX1 represses senescence and promotes SOX2-mediated cellular plasticity during tumorigenesis
por: De Lope, Cristina, et al.
Publicado: (2019)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response
por: Arrizabalaga, Olatz, et al.
Publicado: (2017)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation
por: Reddy, Niyoti, et al.
Publicado: (2021)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Chronic diseases: 2010–2011 progress of the unit for chronic patients and evidence-based medicine of Donostia Hospital/Patologías crónicas: evolución 2010–2011 de la unidad de crónicos y medicina basada en la evidencia del Hospital Donostia
por: Artetxe, Joxe, et al.
Publicado: (2012)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
por: Ryu, Chung Heon, et al.
Publicado: (2012)

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells
por: Qiu, Zhi-Kun, et al.
Publicado: (2014)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
por: Xu, Haoyue, et al.
Publicado: (2022)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance
por: Stepanenko, Aleksei A., et al.
Publicado: (2019)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT
por: Álvarez-Torres, María del Mar, et al.
Publicado: (2021)

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
por: Tancredi, Alessandro, et al.
Publicado: (2022)

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
por: Han, Xinyu, et al.
Publicado: (2023)

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity
por: Cardia, Andrea, et al.
Publicado: (2023)

SOX9 promotes tumor progression through the axis BMI1-p21(CIP)
por: Aldaz, Paula, et al.
Publicado: (2020)

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
por: Wang, Ke, et al.
Publicado: (2017)

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
por: Calegari, M A, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dm60rlb9n67fkrvee45gm1jfi2